91 related articles for article (PubMed ID: 28606707)
1. Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment.
Kozick Z; Hashmi A; Dove J; Hunsinger M; Arora T; Wild J; Shabahang M; Blansfield J
Am J Surg; 2018 Apr; 215(4):686-692. PubMed ID: 28606707
[TBL] [Abstract][Full Text] [Related]
2. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
[No Abstract] [Full Text] [Related]
3. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
4. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
5. Adherence Disparities and Utilization Trends of Oncotype Dx Assay: A National Cancer Database Study.
Chen S; Thacker C; Wang S; Young KA; Hoffman RL; Blansfield JA
J Surg Res; 2023 Jun; 286():65-73. PubMed ID: 36758322
[TBL] [Abstract][Full Text] [Related]
6. Underutilization of gene expression profiling for early-stage breast cancer in California.
Cress RD; Chen YS; Morris CR; Chew H; Kizer KW
Cancer Causes Control; 2016 Jun; 27(6):721-7. PubMed ID: 27097910
[TBL] [Abstract][Full Text] [Related]
7. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
[TBL] [Abstract][Full Text] [Related]
8. Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.
Acuna N; Plascak JJ; Tsui J; Stroup AM; Llanos AAM
Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34065945
[TBL] [Abstract][Full Text] [Related]
9. Low utility of Oncotype DX® in the clinic.
Ricks-Santi LJ; McDonald JT
Cancer Med; 2017 Mar; 6(3):501-507. PubMed ID: 28145091
[TBL] [Abstract][Full Text] [Related]
10. Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?
Kapadia S; Gudiwada SP; Kaji AH; Chlebowski RT; Venegas R; Ozao-Choy J; Dauphine C
Breast J; 2020 Nov; 26(11):2199-2202. PubMed ID: 33001531
[TBL] [Abstract][Full Text] [Related]
11. Influence of provider factors and race on uptake of breast cancer gene expression profiling.
Reeder-Hayes KE; Wheeler SB; Baggett CD; Zhou X; Meng K; Roberts MC; Carey LA; Meyer AM
Cancer; 2018 Apr; 124(8):1743-1751. PubMed ID: 29338090
[TBL] [Abstract][Full Text] [Related]
12. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
13. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Troester MA; Carey LA; Wheeler SB
Breast Cancer Res Treat; 2015 Aug; 153(1):191-200. PubMed ID: 26216535
[TBL] [Abstract][Full Text] [Related]
14. Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.
Robertson SJ; Pond GR; Hilton J; Petkiewicz SL; Ayroud Y; Kos Z; Gravel DH; Stober C; Vandermeer L; Arnaout A; Clemons M
Clin Breast Cancer; 2020 Feb; 20(1):61-67. PubMed ID: 31551182
[TBL] [Abstract][Full Text] [Related]
15. Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
Zipkin R; Schaefer A; Chamberlin M; Onega T; O'Malley AJ; Moen EL
Cancer Med; 2021 Feb; 10(4):1253-1263. PubMed ID: 33455068
[TBL] [Abstract][Full Text] [Related]
16. Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities?
Freeman JQ; Huo D
Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):635-637. PubMed ID: 38689576
[TBL] [Abstract][Full Text] [Related]
17. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
[TBL] [Abstract][Full Text] [Related]
19. How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients.
Zhu X; Dent S; Paquet L; Zhang T; Tesolin D; Graham N; Aseyev O; Song X
Curr Oncol; 2021 Feb; 28(1):800-812. PubMed ID: 33557029
[TBL] [Abstract][Full Text] [Related]
20. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]